Can telehealth help treat opioid addiction in rural and minority areas?
NCT ID NCT07169409
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is testing whether a telehealth platform can help people with opioid use disorder, especially those in rural areas and Black and Hispanic communities, start and stay on buprenorphine treatment. Researchers will enroll 250 participants and measure how acceptable and feasible the program is. The goal is to improve access to care and reduce health disparities.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- buprenorphine
- What this could lead to
- If successful, this could show that telehealth is a practical way to deliver opioid use disorder treatment to underserved communities, improving access and equity.
- What could go wrong
- This is an early-phase study focused on feasibility and acceptability, not on proving the treatment works. The results may not apply to all settings or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * History of Opioid Use Disorder (OUD) * Starting OUD treatment with buprenorphine, or within 45 days of starting or restarting this medication * Speak and understand English Exclusion Criteria: * History of allergic reaction to buprenorphine * Plans to move out of a Boulder Care-affiliated state site in the next 12 months (precluding continuation of care) * Untreated mental or medical health conditions that, in the opinion of the participant, would preclude study participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Opioid use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Boulder Care
RECRUITINGPortland, Oregon, 97204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise boost brain and body health during opioid treatment?
- Can a new drug calm the storm of opioid withdrawal?
- Can coaching turn rural clinics into One-Stop shops for addiction and infectious disease care?
- Can a Phone-Based platform keep people in opioid treatment?
- A safety net after jail: can checkups keep opioid treatment on track?
- Can AI and peer support close the opioid treatment gap?